Catalyst Repository | Allena Pharmaceuticals Inc. Common Stock

Allena Pharmaceuticals Inc. Common Stock

(NASDAQ:ALNA)

Description

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.

ALNA Overview

None
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Previous Close
$0.1250
Previous Close Volume
17600000